In order to investigate how galectin-3 activates ECs to regulate vascular remodeling in BLM-induced IPF, we examined the protein expression of ECs and mesenchymal biomarkers along with regulators of the AKT/GSK3β/β-catenin singling pathway after treatment with the galectin-3 antagonist GB1107 or vehicle (DMSO). The gene discussed is AKT1; the disease is idiopathic pulmonary fibrosis.